AAAAAA

   
Results: 1-8 |
Results: 8
Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen
Authors: Shah, AA Thjodleifsson, B Murray, FE Kay, E Barry, M Sigthorsson, G Gudjonsson, H Oddsson, E Price, AB Fitzgerald, DJ Bjarnason, I
Citation: Aa. Shah et al., Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen, GUT, 48(3), 2001, pp. 339-346
Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease - A double-blind, multicenter, European trial
Authors: Thjodleifsson, B Beker, JA Dekkers, C Bjaaland, T Finnegan, V Humphries, TJ
Citation: B. Thjodleifsson et al., Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease - A double-blind, multicenter, European trial, DIG DIS SCI, 45(5), 2000, pp. 845-853
A simple method for assessing intestinal inflammation in Crohn's disease
Authors: Tibble, J Teahon, K Thjodleifsson, B Roseth, A Sigthorsson, G Bridger, S Foster, R Sherwood, R Fagerhol, M Bjarnason, I
Citation: J. Tibble et al., A simple method for assessing intestinal inflammation in Crohn's disease, GUT, 47(4), 2000, pp. 506-513
Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract
Authors: Bjarnason, I Thjodleifsson, B
Citation: I. Bjarnason et B. Thjodleifsson, Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract, RHEUMATOLOG, 38, 1999, pp. 24-32
Review article: rabeprazole's tolerability profile in clinical trials
Authors: Thjodleifsson, B Cockburn, I
Citation: B. Thjodleifsson et I. Cockburn, Review article: rabeprazole's tolerability profile in clinical trials, ALIM PHARM, 13, 1999, pp. 17-23
Double-blind, comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of erosive or ulcerative gastrooesophageal reflux disease (vol13, pg 49, 1999)
Authors: Dekkers, CPM Beker, JA Thjodleifsson, B Gabryelewicz, A Bell, NE Humphries, TJ
Citation: Cpm. Dekkers et al., Double-blind, comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of erosive or ulcerative gastrooesophageal reflux disease (vol13, pg 49, 1999), ALIM PHARM, 13(4), 1999, pp. 567-567
Comparison of rabeprazole 20mg versus omeprazole 20mg in the treatment of active duodenal ulcer: a European multicentre study
Authors: Dekkers, CPM Beker, JA Thjodleifsson, B Gabryelewicz, A Bell, NE Humphries, TJ
Citation: Cpm. Dekkers et al., Comparison of rabeprazole 20mg versus omeprazole 20mg in the treatment of active duodenal ulcer: a European multicentre study, ALIM PHARM, 13(2), 1999, pp. 179-186
Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease
Authors: Dekkers, CPM Beker, JA Thjodleifsson, B Gabryelewicz, A Bell, NE Humphries, TJ
Citation: Cpm. Dekkers et al., Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease, ALIM PHARM, 13(1), 1999, pp. 49-57
Risultati: 1-8 |